Skip to content
HowShorted

ARS Pharmaceuticals, Inc. short interest in 2023

In 2023, ARS Pharmaceuticals, Inc.'s disclosed short interest ran from 4.29% of shares outstanding on 13 Jan 2023 to 7.26% on 29 Dec 2023, a change of +2.97 percentage points. The year's high was 7.26% on 29 Dec 2023 and its low 2.47% on 31 Mar 2023, averaging 5.38% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.95 days on 29 Dec 2023. Full history: ARS Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ARS Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
4.29% (13 Jan 2023)
End of year
7.26% (29 Dec 2023)
Change
+2.97 pp
High
7.26% (29 Dec 2023)
Low
2.47% (31 Mar 2023)
Average
5.38%
Highest days to cover
20.95 (29 Dec 2023)
SEC filings marked
9

Every report in 2023

ARS Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20234.29%5.24
31 Jan 20234.34%8.38
15 Feb 20234.70%7.07results (8-K)
28 Feb 20234.63%6.56
15 Mar 20235.50%9.71
31 Mar 20232.47%8.5210-K filed, results (8-K)
14 Apr 20232.84%10.56
28 Apr 20233.30%10.61
15 May 20233.84%1.0010-Q filed, results (8-K)
31 May 20234.70%3.59
15 Jun 20235.74%8.43
30 Jun 20236.28%5.79
14 Jul 20236.61%13.07
31 Jul 20236.43%16.30
15 Aug 20236.09%18.6310-Q filed, results (8-K)
31 Aug 20235.62%16.30
15 Sep 20236.04%7.31
29 Sep 20236.14%1.16
13 Oct 20235.93%6.47
31 Oct 20236.91%13.72
15 Nov 20236.18%5.9010-Q filed, results (8-K)
30 Nov 20236.28%12.22
15 Dec 20236.96%14.56
29 Dec 20237.26%20.95

See also: ARS Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.